Loading…
MTVA
MetaVia Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 64132R503
$1.70+2.41%Price as of Aug 29, 18:48 UTC · updated once a day, after the close
Key metrics
- Market cap
- $11.2M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.45
- ROE
- -175.68%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.90
- 52-week high
- $19.03
- 52-week low
- $0.97
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.17▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 10 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.42 | $22.33 | $40.67 | $63.18 | $3,220.80 | $13,860.00 | $23,100.00 | $53,460.00 | $524,370.00 | $517,440.00 | |
| P/B | 3.5x | 8.0x | 2.2x | 1.1x | 0.9x | 2.2x | 16.2x | 11.2x | — | 4530.6x | 3.5x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VTGNVistagen Therapeutics, Inc. | $0.25 | — | 0.5x | — | -166.46% | $11.22M |
| TOVXTheriva Biologics, Inc. | $0.25 | 0.2x | 0.9x | — | -101.87% | $11.25M |
| ADGMAdagio Medical Holdings, Inc. | $0.51 | — | — | — | -657.76% | $11.35M |
| BLRXBioLineRx Ltd. | $2.60 |
About the company
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- 8
- Cambridge, United States
Company description provided by Yahoo Finance.